MBHB Attorney Taylor Weilnau Comments on Supreme Court’s Skinny Label Ruling in Law360

In Law360, MBHB attorney Taylor Weilnau weighs in on the U.S. Supreme Court’s unanimous decision in Hikma Pharmaceuticals USA Inc. v. Amarin Pharma Inc., which reversed a Federal Circuit ruling and held that Hikma did not plausibly induce infringement of Amarin’s patents on the heart drug Vascepa. Weilnau notes that the decision is more instructive about what conduct falls short of inducement than about what would satisfy the standard. Read the article.